Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 53.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 755,691 shares of the company’s stock after selling 858,622 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.20% of Moderna worth $31,422,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. State Street Corp grew its position in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after buying an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Moderna by 6.2% during the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after buying an additional 178,939 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MRNA. Morgan Stanley lowered their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Sanford C. Bernstein began coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Finally, Argus cut Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $66.89.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $30.93 on Wednesday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a twelve month low of $30.70 and a twelve month high of $170.47. The stock has a 50 day moving average of $39.77 and a two-hundred day moving average of $56.76. The stock has a market cap of $11.90 billion, a P/E ratio of -5.31 and a beta of 1.59.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.20% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.